Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC).

被引：2
|
作者：
Hirose, T. [1 ]
Shirai, T. [1 ]
Kusumoto, S. [1 ]
Sugiyama, T. [1 ]
Yamaoka, T. [1 ]
Okuda, K. [1 ]
Ohmori, T. [1 ]
Ohnishi, T. [1 ]
Adachi, M. [1 ]
机构：
[1] Showa Univ, Sch Med, Tokyo 142, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7057
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer
    Mori, K
    Kamiyama, Y
    Kondo, T
    Kano, Y
    Kodama, T
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (01) : 86 - 90
  • [32] Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer
    Kiyoshi Mori
    Yukari Kamiyama
    Tetsuro Kondo
    Yasuhiko Kano
    Tetsuro Kodama
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 86 - 90
  • [33] A phase II study of irinotecan (CPT-11) and doxorubicin (DXR) in patients with refractory or relapsed small-cell lung cancer (SCLC).
    Negoro, S
    Uejima, H
    Takeda, K
    Miyazaki, M
    Takihuji, N
    Hirashima, T
    Matsui, K
    Fukuoka, M
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [34] Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC).
    Kim, Y.
    Goto, K.
    Nishiwaki, Y.
    Kubota, K.
    Omatsu, H.
    Tamura, T.
    Ohe, Y.
    Kunitoh, H.
    Sekine, I.
    Yamamoto, N.
    Saijo, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 386S - 386S
  • [35] A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer
    Inoue, Akira
    Yamazaki, Koichi
    Maemondo, Makoto
    Suzuki, Takuji
    Kimura, Yuichiro
    Kanbe, Mariko
    Isobe, Hiroshi
    Nishimura, Masaharu
    Saijo, Yasuo
    Nukiwa, Toshihiro
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (06) : 551 - 555
  • [36] Phase I study of amrubicin (AMR) for patients (pts) with previously treated small cell lung cancer (SCLC)
    Katakami, N.
    Hata, A.
    Yoshioka, H.
    Higashi, Y.
    Nishimura, T.
    Sakaguchi, S.
    Hayashi, M.
    Tomii, K.
    Naya, R.
    Ishihara, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Epirubicin combined with ifosfamide in relapsed or refractory small cell lung cancer (SCLC) patients
    Jacot, William
    Molinier, Olivier
    Colinet, Benoit
    Bozonnat, Marie-Cecile
    Quantin, Xavier
    Gervais, Radj
    Pujol, Jean-Louis
    ANNALS OF ONCOLOGY, 2006, 17 : 232 - 233
  • [38] Multicentre phase II study of carboplatin (AUC 5) and vinorelbine in small cell lung cancer (SCLC)
    Dunlop, DJ
    O'Brien, ME
    Lee, SM
    Hill, S
    Thatcher, N
    BRITISH JOURNAL OF CANCER, 2000, 83 : 42 - 42
  • [39] A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
    Kim, Yu-Jung
    Keam, Bhumsuk
    Ock, Chan-Young
    Song, Sanghoon
    Kim, Miso
    Kim, Se Hyun
    Kim, Ki Hwan
    Kim, Jin-Soo
    Kim, Tae Min
    Kim, Dong-Wan
    Lee, Jong Seok
    Heo, Dae Seog
    LUNG CANCER, 2019, 136 : 122 - 128
  • [40] Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer
    Yamamoto, N
    Tsurutani, J
    Yoshimura, N
    Asai, G
    Moriyama, A
    Nakagawa, K
    Kudoh, S
    Takada, M
    Minato, Y
    Fukuoka, M
    ANTICANCER RESEARCH, 2006, 26 (1B) : 777 - 781
12345